Skip to main content

Tessera

corporate_fare Company Profile

Tessera

HLSQ·OTC·Technology·CIK 0001739174

Tessera is a clinical-stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI. Bacteriophage, or phage, are bacterial, species-specific, strain-limited viruses that infect, amplify and kill target bacteria and are considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and by creating novel phage using synthetic biology, Tessera develops phage-based therapies intended to address large-market diseases. Based on the urgency of treating the infection (whether acute or chronic), the susceptibility of the target bacteria to phage (e.g. the ability to identify a phage cocktail that would target a broad range of bacterial strains) and other considerations, Tessera offers two phage-based product types. The first is fixed cocktail therapy, in which a single product containing a fixed number of selected phages is developed to cover a wide range of bacterial strains, allowing treatment of broad patient populations with the same product; fixed cocktails are developed using Tessera's platform, in which high throughput screening, directed evolution, and bioinformatic approaches are leveraged to produce an optimal phage cocktail. The second is personalized therapy, in which a large library of phages is developed and single optimal phages are personally matched to treat specific patients; matching optimal phages with patients is carried out using proprietary phage susceptibility testing, or patient specific targeting, where multiple considerations are analyzed simultaneously, allowing for an efficient screen of the phage library while maintaining short turnaround times. In its therapeutic programs, Tessera focuses on using phage therapy to target specific strains of pathogenic bacteria associated with diseases. Its phage-based product candidates are developed utilizing its proprietary research and development platform, which employs methodologies and capabilities across computational biology, microbiology, synthetic engineering of phage and their production bacterial hosts, bioanalytical assay development, manufacturing and formulation to allow agile and efficient development of natural or engineered phage combinations, or cocktails.

Tessera (OTC:HLSQ) is a publicly traded company in the Technology sector. Wiseek has independently scored 1 item for HLSQ at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10.

Recent high-impact activity:

  • NYSE Delisting Notice Hits Micro-Cap Tessera

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$36.2M
Diluted EPS
$22.19
Op. Cash Flow
-$26.39M
Free Cash Flow
-$26.39M
Operating Income
-$41.47M
Cash & Equivalents
$4.36M
Debt / Equity
0.00×
Shares Outstanding
1.59M sh
Source: 10-K · filed 2026-04-30 · accession 0001213900-26-050373

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 88,797 shares in HLSQ as of the October 30, 2026 settlement, a 70.9% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 33.3% of HLSQ volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)88,797 shares as of October 30, 2026
Change vs prior period▼ 70.9%
Days to cover1.00 at avg daily volume of 1,619,435
Daily short volume (FINRA facilities)33.3% of 243,885 shares on November 20, 2026
5-day average short volume21.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.018 -14.29% today
52-week range · as of 2026-11-20 $0.0161 – $1.75
Market cap
$467.92K
Volume
243.9K (0.2× avg)
3-mo avg 1.1M
Live data · 2026-11-22 10:31 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HLSQ - Latest Insights

HLSQ
Nov 20, 2026, 4:17 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $0.018
Real-time Price: $0.018 info
Change: $0 (0%) info
Market Cap: $467.924K info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets